A Novel Intercellular Communication-Associated Gene Signature for Prognostic Prediction and Clinical Value in Patients With Lung Adenocarcinoma
Source check: Source checked. Not independent scientific confirmation.
Finding: Multi-dataset machine-learning and intercellular-communication analysis identified lung-adenocarcinoma genes associated with prognosis and immune-cell signaling; these remain candidate associations.
Technology: The original Methods describe the learning operation and Results connect it to the specific disease or outcome finding.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- The original Methods describe the learning operation and Results connect it to the specific disease or outcome finding.
- Test and result
- Full-text Results were examined for outcome, data/cohort and scope.
- Limitation / still unknown
- Reported comparison, experimental confirmation or held-out evaluation was checked; reason limits interpretation to the evidence.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.3389/fgene.2021.702424 · https://europepmc.org/article/MED/34497634 · https://europepmc.org/articles/PMC8419521 · https://www.ncbi.nlm.nih.gov/research/bionlp/RESTful/pmcoa.cgi/BioC_json/PMC8419521/unicode · https://pubmed.ncbi.nlm.nih.gov/34497634/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.